Diana Campelo Delgado,  —

Targeting the calcium‐sensing receptor (CaSR), which plays a critical role in the development of bone cells, may be a therapeutic strategy to slow the progression of ankylosing spondylitis (AS), a study suggests. The study, “Aberrant upregulation of CaSR promotes pathological new bone formation in ankylosing spondylitis,” was published…

AbbVie’s Rinvoq (upadacitinib) has been recommended for approval in the European Union as a treatment for active ankylosing spondylitis (AS) in adults. The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, also supports Rinvoq’s approval to treat adults with active psoriatic…